Pradigastat

Drug Profile

Pradigastat

Alternative Names: LCQ 908; LCQ908-NXA; LCQ908A; Pradigastat sodium

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Aminopyridines; Antihyperglycaemics; Antihyperlipidaemics; Cyclohexanecarboxylic acids; Obesity therapies; Small molecules
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipoproteinaemia type I
  • No development reported Coronary artery disease; Hyperlipoproteinaemia type V; Hyperlipoproteinaemias; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus
  • Discontinued Hepatitis C

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 11 Sep 2015 No recent reports on development identified - Phase-I/II for Hyperlipoproteinaemia type V in Canada (PO)
  • 12 May 2015 Phase-III is still ongoing for Hyperlipoproteinaemia type I in the United Kingdom, Spain, Canada, Netherlands and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top